In the last two decades, advances in lung cancer therapeutics have led to the adaptation of comprehensive molecular profiling of novel driver mutations, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been shown to improve overall response rate and median progression-free survival when compared with platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations [3,4,5,6,7,8,9,10]. The gene discussed is EGFR; the disease is lung cancer.